Switch theme
Sign up to access all valuation multiples
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.
1996
714
LTM Revenue $178M
LTM EBITDA -$13.4M
$443M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oxford BioMedica has a last 12-month revenue of $178M and a last 12-month EBITDA of -$13.4M.
In the most recent fiscal year, Oxford BioMedica achieved revenue of $115M and an EBITDA of -$191M.
Oxford BioMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oxford BioMedica valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $180M | $115M | XXX | XXX | XXX |
| Gross Profit | $106M | $89.1M | XXX | XXX | XXX |
| Gross Margin | 59% | 77% | XXX | XXX | XXX |
| EBITDA | -$14.0M | -$191M | XXX | XXX | XXX |
| EBITDA Margin | -8% | -166% | XXX | XXX | XXX |
| Net Profit | $24.5M | -$50.4M | XXX | XXX | XXX |
| Net Margin | 14% | -44% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oxford BioMedica's stock price is GBP 3 (or $4).
Oxford BioMedica has current market cap of GBP 296M (or $381M), and EV of GBP 344M (or $443M).
See Oxford BioMedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $443M | $381M | XXX | XXX | XXX | XXX | $-0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oxford BioMedica has market cap of $381M and EV of $443M.
Oxford BioMedica's trades at 2.5x LTM EV/Revenue multiple, and -32.9x LTM EBITDA.
Analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oxford BioMedica and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $443M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -9.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOxford BioMedica's NTM/LTM revenue growth is 26%
Oxford BioMedica's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Oxford BioMedica's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oxford BioMedica and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -36% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -166% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1268% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -140% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 66% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 140% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxford BioMedica acquired XXX companies to date.
Last acquisition by Oxford BioMedica was XXXXXXXX, XXXXX XXXXX XXXXXX . Oxford BioMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oxford BioMedica founded? | Oxford BioMedica was founded in 1996. |
| Where is Oxford BioMedica headquartered? | Oxford BioMedica is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Oxford BioMedica have? | As of today, Oxford BioMedica has 714 employees. |
| Who is the CEO of Oxford BioMedica? | Oxford BioMedica's CEO is Dr. Frank Mathias. |
| Is Oxford BioMedica publicy listed? | Yes, Oxford BioMedica is a public company listed on LON. |
| What is the stock symbol of Oxford BioMedica? | Oxford BioMedica trades under OXB ticker. |
| When did Oxford BioMedica go public? | Oxford BioMedica went public in 2001. |
| Who are competitors of Oxford BioMedica? | Similar companies to Oxford BioMedica include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Oxford BioMedica? | Oxford BioMedica's current market cap is $381M |
| What is the current revenue of Oxford BioMedica? | Oxford BioMedica's last 12-month revenue is $178M. |
| What is the current EBITDA of Oxford BioMedica? | Oxford BioMedica's last 12-month EBITDA is -$13.4M. |
| What is the current EV/Revenue multiple of Oxford BioMedica? | Current revenue multiple of Oxford BioMedica is 2.5x. |
| What is the current EV/EBITDA multiple of Oxford BioMedica? | Current EBITDA multiple of Oxford BioMedica is -32.9x. |
| What is the current revenue growth of Oxford BioMedica? | Oxford BioMedica revenue growth between 2023 and 2024 was -36%. |
| Is Oxford BioMedica profitable? | Yes, Oxford BioMedica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
